Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dan Hudson

MBiochem. MSc.

DPhil Student


Dan Hudson is a 3rd year DPhil candidate on the prestigious BBSRC Interdisciplinary Bioscience Doctoral Training Programme at the University of Oxford. Dan holds first-class degrees in Biochemistry (M.Biochem, Oxford, 2010) and artificial intelligence (MSc., Queen Mary University of London, 2020), returning to full-time academic research in 2021 after more than ten years in the pharmaceutical industry. 

Inspired by his studies at QMUL, Dan left a senior position at GSK Vaccines R&D to pursue independent research in the field of computational immunology. This latest challenge allows him to combine postgraduate studies in T cell biology (Davis group, MRC Weatherall Institute of Molecular Medicine, 2009) and machine learning (Gong group, QMUL 2018-20) with considerable industry expertise. 

Research interests

In order to fight off attacks by the microscopic bugs that cause disease, and to find and eliminate cancers, specialist cells of the immune system need to be able to recognise these invaders as foreign or abnormal. This is achieved using molecules on their outward facing cell membranes, known as receptors.

Dan's PhD research will rely on the use of powerful algorithms to understand the types of immune cell receptors found in the human body during health and disease. The hope is that this will help identify new immune signatures of disease, and inform the use of these receptors for new drug development.

In particular, Dan is interested in the application of machine learning techniques to dissect the binding preferences of human T cell receptors (TCRs) implicated in human disease, and in the development of novel TCR therapies.

Recent publications

More publications